The next webinar in the COVID-19 web series will discuss treatment of critical care and pregnant patients with COVID-19 and possible implications in pregnancy.
- Understand more about treating patients diagnosed with COVID-19
- Learn how best to manage patients in critical care
- Understand the impact of thrombosis in COVID-19 patients
- Hear the latest research on pharmacology and therapeutics
- Understand more what medication to use
- Hear the global perspective on how patients are treated in low and middle-income countries
- Ask questions to the expert panel
Watch the fifth English webinar in the COVID-19 web series
|11:00-11:05||Welcome and introduction||
Prof. Tom Bourne, Prof. Christoph Lees
|11:05-11:15||Critical Care in adults with COVID-19||Dr Nick Barrett|
|11:15-11:25||Impact of COVID-19 on pregnancy care in LMIC||Dr Hema Divakar|
|11:25-11:35||Thrombosis in COVID-19 & implications in pregnancy||Prof. Beverley Hunt|
|11:35-11:45||Pharmacology & Therapeutics in pregnancy with COVID-19||Prof. David Williams|
2020 Virtual Congress Technical Congress Chair, Bids Committee, Executive Committee, Finance & Risk Committee, Nominations Committee, Governance group
Prof. Tom Bourne is an authority on early pregnancy complications, emergency gynecology and gynaecological ultrasound. He is known both nationally and internationally for his expertise in terms of “hands on” clinical care and his extensive clinical research. He has edited seven books and published over 300 papers.
In 1994 he worked at University of Göteborg, Sweden as Swedish Medical Research Council visiting scientist. He wrote his Ph.D. on detecting ovarian & endometrial cancer. Following this, he was appointed consultant gynaecologist at St George's University Hospital, London in 1996, he obtained MRCOG in 1990 and FRCOG in 2003. Prof. Bourne was appointed Reader in acute gynecology & gynaecological ultrasonography at University of London (2005) & Visiting Professor at KU Leuven, Belgium (2007). In 2014 he was awarded honorary fellowship of the American Institute of Ultrasound in Medicine (AIUM) & honorary membership of Australasian Society for Ultrasound in Medicine (ASUM) in 2016.
He is President of the UK Association of Early Pregnancy Units (AEPU), Trustee of the Ectopic Pregnancy Trust and on the steering committee of the International Ovarian Tumor Analysis (IOTA) trial.
Director of Guy's and St Thomas' Haemostasis Research Unit, clinical lead for haematological services at Viapath and sits on the Viapath Analytics operating board.
Executive Committee, Finance & Risk Committee (Chair), Safety Committee (Chair), Scientific Committee, Governance group, Perinatal Doppler and Vascular Focus Group (Chair), UOG Editorial Board
Christoph Lees is a Maternal-Fetal Medicine subspecialist, Consultant Obstetrician and Head of Fetal Medicine at Imperial College London where he is Clinical Reader. He is visiting Professor, KU Leuven, Belgium, was RCOG inaugural National Ultrasound Officer 2010-2013 and Vice Chairman, RCOG Subspecialty Committee 2011-2013. His research focuses on pre-eclampsia, cardiovascular adaptation, Doppler, intra-uterine growth restriction and non-invasive fetal surgery.
Specialties: Fetal anomaly screening T2; fetal biometry and wellbeing; aneuploidies; fetal anomalies; fetal growth restriction; maternal and fetal Doppler; preeclampsia; safety of ultrasound
Scientific Committee, UOG Editorial Board
Professor Liona Poon is an Academic Subspecialist in Maternal Fetal Medicine, devoted in improving maternal and fetal health. She has had a prolific research output throughout her clinical and research posts, including over 130 peer-reviewed publications in high impact international journals. In the last 10 years she has focused her research on establishing a programme for effective early prediction and prevention of preeclampsia, a major cause of maternal and perinatal morbidity and mortality. With her success in developing a first-trimester prediction model for preeclampsia using maternal risk factors, ultrasound, blood pressure and biochemical markers, and on Aspirin prophylaxis against preeclampsia, her goal in the next 10 years is to improve obstetric care worldwide, through clinical research and education.
Aspire trial: incidence of preterm preeclampsia in patients fulfulling ACOG and NICE criteria according to risk by the FMF algorithm. Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nikolaides KH.
Ultrasound Obstet Gynecol 2018 Jan 30. doi: 10.1002/uog.19019 [Epub ahead of print]
Aspirin versus Placebo in Pregnancies at High Risk of Preterm Preeclampsia. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tennebaum Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides K.H.
New England Journal Medicine 2017, 2017 Jun 28. doi: 10.1056/NEJMoa1704559. [Epub ahead of print]
Country: China, Hong Kong Special Administrative Region
Specialties: Fetal anomaly screening 1st trimester and 2nd trimester; fetal biometry and wellbeing; fetal anomalies screening; aneuploidy screening; fetal anomalies; fetal growth restriction; maternal and fetal Doppler; multiple pregnancy; preeclampsia; preterm delivery; fetal growth; detection of fetal and neonatal growth abnormalities; ultrasound on the labour ward
Languages: English; Chinese (Mandarin); Chinese (Cantonese)